Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy

Mar 27, 2023

Publications

Endogenous viral elements constitute a complementary source of antigens for personalized cancer immunotherapy

Publication: bioRxiv

Authors: Christian Garde, Michail A Pavlidis, Pablo Garces, Emma J Lange, Sri H Ramarathinam, Mateo Sokac, Kirti Pandey, Pouya Faridi, Johanne Ahrenfeldt, Shanzou Chung, Stine Friis, Daniela Kleine-Kohlbrecher, Nicolai J Birkbak, Jens V Kringelum, Birgitte Rono, Anthony W Purcell, Thomas Trolle

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Mar 26, 2023

Press releases

Evaxion presents a new source of AI-derived immunotherapeutic targets strongly associated with the overall survival of cancer patients

Evaxion’s AI technology has led to the identification of new viral targets for cancer immunotherapy

This potentially enables treatment for patients with cold tumors, normally unresponsive to immunotherapy

Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

Mar 15, 2023

Press releases

Evaxion Biotech to announce clinical data for the personalized DNA cancer vaccine EVX-02 at the 2023 American Association for Cancer Research Annual Meeting (AACR)

COPENHAGEN, Denmark, March 14, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-powered immunotherapies, today announced that the company will present clinical readout of the Phase 1/2a trial of EVX-02 at the upcoming 2023 American Association for Cancer Research Annual Meeting (2023 AACR), taking place from April 14th to April 19th in Orlando, Florida.

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Feb 8, 2023

Press releases

Evaxion and Pantherna announce promising preclinical mRNA vaccine data

Evaxion and Pantherna announced that the tumor neoantigens, identified by Evaxion's PIONEER, demonstrates strong immune response

Redeye Fight Cancer – January 2023

Jan 19, 2023

Presentations

Redeye Fight Cancer – January 2023

Our CEO, Per Norlén, presented at Redeye Fight Cancer on January 19, 2023.

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

Jan 3, 2023

Press releases

Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01

Evaxion today announced that the U.S. Food and Drug Administration (“FDA”) determined that the Company may proceed with its Phase 2b clinical trial of EVX-01.

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

Dec 15, 2022

Press releases

Evaxion to present a full clinical readout on two personalized cancer immunotherapies in Q2 2023

Evaxion today announced that they expect to present data from their two clinical trials of personalized cancer immunotherapies (cancer vaccines) EVX-01 and EVX-02 in the second quarter of 2023.

Evaxion and ExpreS<sup>2</sup>ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Dec 6, 2022

Press releases

Evaxion and ExpreS2ion initiate research collaboration on a novel cytomegalovirus (CMV) vaccine candidate

Evaxion has signed a Vaccine Discovery Collaboration Agreement with ExpreS2ion Biotech for the joint development of a novel cytomegalovirus (CMV) vaccine candidate

Get to know CEO Per Norlén

Dec 5, 2022

Presentations

Get to know CEO Per Norlén

Redeye interviewed Evaxion’s newly appointed CEO, Per Norlén, about his background, reasons for joining the company, and hopes for the future

BioStock Life Science Fall Summit 2022

Nov 29, 2022

Presentations

BioStock Life Science Fall Summit 2022

Our CEO, Per Norlén, presented the company at BioStock Life Science Fall Summit 2022 in Lund, Sweden. In the video, you can hear more about how we use the power of our AI  to make a unique and personalized treatment for each patient

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Nov 17, 2022

Press releases

Evaxion announces promising results from Phase 1/2a clinical trial of personalized DNA cancer immunotherapy EVX-02

Evaxion announced today promising clinical data from the Phase 1/2a first-in-human study of its DNA-based cancer immunotherapy, EVX-02.

Benchmarking freely available HLA typing algorithms across varying genes, coverages and typing resolutions

Nov 16, 2022

Publications

Benchmarking freely available HLA typing algorithms across varying genes, coverages and typing resolutions

Publication: Frontiers in Immunology
Authors: Nikolas Hallberg Thuesen, Michael Schantz Klausen, Shyam Gopalakrishnan, Thomas Trolle and Gabriel Renaud

Subscribe to our Newsletter

Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.